Payment overview · 2025
General Payments
$5,165.06
16 reported records · 8 companies
Healthcare provider profile · identity verified
Manuel Antonio Suarez Barcelo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH MIAMI, FL · NPI 1669461042
Verified facts
What the public records show
CMS Open Payments records show Manuel Antonio Suarez Barcelo, MD received $5,165.06 in general payments during 2025 across 16 reported records.
Viatris Specialty LLC accounted for 93.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $4,844.28 | 93.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.94 | 2.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $48.72 | 0.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.46 | 0.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.60 | 0.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.64 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.78 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.64 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,903.88 | 2 |
| Travel and Lodging | $796.86 | 2 |
| Food and Beverage | $464.32 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $4,844.28 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $148.94 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $48.72 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
138 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 71 |
| Metformin Hcl | Metformin Hcl | 366 | 60 |
| Gemtesa | Vibegron | 331 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 303 | 40 |
| Eliquis | Apixaban | 245 | 24 |
| Gabapentin | Gabapentin | 211 | 26 |
| Mirtazapine | Mirtazapine | 211 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 33 |
| Trazodone Hcl | Trazodone Hcl | 205 | 33 |
| Levetiracetam | Levetiracetam | 199 | 25 |
| Risperidone | Risperidone | 199 | 25 |
| Xarelto | Rivaroxaban | 197 | 14 |
| Lisinopril | Lisinopril | 196 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 41 |
| Furosemide | Furosemide | 190 | 37 |
| Losartan Potassium | Losartan Potassium | 186 | 46 |
| Omeprazole | Omeprazole | 169 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 37 |
| Benztropine Mesylate | Benztropine Mesylate | 148 | 21 |
| Trulicity | Dulaglutide | 138 | 16 |
| Lactulose | Lactulose | 131 | 16 |
| Potassium Chloride | Potassium Chloride | 124 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 19 |
| Farxiga | Dapagliflozin Propanediol | 111 | suppressed |
| Clonazepam | Clonazepam | 107 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 20 |
| Divalproex Sodium | Divalproex Sodium | 99 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 24 |
| Allopurinol | Allopurinol | 95 | 16 |
| Finasteride | Finasteride | 95 | 12 |
| Famotidine | Famotidine | 89 | 16 |
| Clozapine | Clozapine | 87 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 87 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 85 | 18 |
| Nifedipine Er | Nifedipine | 84 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 81 | suppressed |
| Memantine Hcl | Memantine Hcl | 78 | 12 |
| Sertraline Hcl | Sertraline Hcl | 76 | 14 |
| Latanoprost | Latanoprost | 75 | 11 |
| Haloperidol | Haloperidol | 74 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 73 | suppressed |
| Lorazepam | Lorazepam | 71 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 11 |
| Azithromycin | Azithromycin | 63 | 49 |
| Temazepam | Temazepam | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Simvastatin | Simvastatin | 55 | 13 |
| Carvedilol | Carvedilol | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Novolog Flexpen | Insulin Aspart | 51 | suppressed |
| Alprazolam | Alprazolam | 50 | 13 |
| Atenolol | Atenolol | 49 | 11 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Tivicay | Dolutegravir Sodium | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 40 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 31 |
| Clonidine Hcl | Clonidine Hcl | 38 | 13 |
| Risperdal Consta | Risperidone Microspheres | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 13 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Naproxen | Naproxen | 35 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Mupirocin | Mupirocin | 32 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Procrit | Epoetin Alfa | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Prilosec | Omeprazole Magnesium | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Risperidone Er | Risperidone Microspheres | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,165.06 · 16 records | Viatris Specialty LLC | ABRYSVO, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Kerendia, MOUNJARO, PREVNAR 20, REPATHA, YUPELRI, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error